Tag Archives: hiv

July, 2016

June, 2016

April, 2016

  • 25 April

    European Commission Grants Marketing Authorization for Gilead’s Treatment for HIV

    FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted marketing authorization for two doses of Descovy® (emtricitabine and tenofovir alafenamide 200/10 mg and 200/25 mg; F/TAF), a fixed-dose combination for the treatment of HIV-1 infection. Descovy is Gilead’s second TAF-based therapy to receive …

  • 5 April

    Gilead’s HIV Therapy Descovy Receives FDA Approval

    FOSTER CITY, Calif.–(BUSINESS WIRE)–Apr. 4, 2016– Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg, F/TAF), a fixed-dose combination for the treatment of HIV. Descovy is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in …

March, 2016

  • 22 March

    Pfizer Joins the Human Vaccines Project to Help Decode the Immune System

    NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) today announced it will join the Human Vaccines Project (the Project), a public-private consortium focused on cross-sector collaboration to identify human immune responses associated with optimal vaccine protection. Insights gained will guide the development of potentially improved vaccines against diseases such as influenza, dengue, HIV …

  • 2 March

    FDA Approves Gilead’s Single-Pill HIV Therapy Odefsey

    FOSTER CITY, Calif.–(BUSINESS WIRE)–Mar. 1, 2016– Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Odefsey® (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients. Emtricitabine and tenofovir alafenamide are from Gilead Sciences …

January, 2016

  • 15 January

    New Study Finds Additional Insights for AIDS Vaccine Design

    NEW YORK, Jan. 15, 2016 /PRNewswire-USNewswire/ — A new study helps AIDS vaccine researchers further understand how HIV interacts with its host, and how some people naturally produce antibodies against the virus’ many variants. The study, authored by researchers from the International AIDS Vaccine Initiative (IAVI) and partners, was published …

  • 8 January

    Viiv and Janssen Collaborate to Develop HIV Maintenance Therapy

    CORK, Ireland, January 7, 2016 /PRNewswire/ — Results from ongoing phase IIb Week 32 study show that if successfully developed and approved, people living with HIV could potentially maintain viral suppression Janssen Sciences Ireland UC (Janssen), today formalized its collaboration with ViiV Healthcare on phase III development and commercialization of …